Niagen's ChromaDex Acquires Nicotinamide Riboside Patents From Queen's University Belfast

Niagen Bioscience Acquires Core Nicotinamide Riboside Patent Portfolio

Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (Nr) Patent Portfolio From Queen’s University Belfast

Niagen Bioscience management to meet with Roth Capital

Niagen Bioscience Announces $10 Million Share Repurchase Program

Niagen Bioscience CFO Pamir Ozan Acquires Common Shares

Correction: Niagen Says Long COVID Trial Exploring Supplement Failed to Show 'Statistically Significant Differences' in Meeting Endpoints Versus Placebo Groups

Niagen Bioscience announces results of Niagen supplementation in long COVID

Niagen Bioscience Reports Clinical Trial Shows Niagen Supplement Boosts NAD+ and Eases Long COVID Symptoms

Niagen Bioscience Approves $10 Million Stock Buyback Program

Stock Track | Niagen Bioscience Soars 6.25% Following $10 Million Share Repurchase Announcement

Stock Track | Niagen Bioscience Soars 6.25% on $10 Million Share Repurchase Program Announcement

Niagen Bioscience Announces $10 Million Share Buyback

Stock Track | Niagen Bioscience Soars 6.10% Pre-market on $10 Million Share Repurchase Announcement

Stock Track | Niagen Bioscience Soars 6.10% Pre-market on $10 Million Share Buyback Announcement

BRIEF-Niagen Bioscience Announces $10 Million Share Repurchase Program

Niagen Bioscience Inc. Publishes Transcript of Third Quarter 2025 Earnings Conference Call

Niagen Bioscience Is Maintained at Buy by Canaccord Genuity

Niagen Bioscience price target lowered to $14 from $16 at Canaccord